Doximity Facing Limited Clarity on AI Projects, BofA Says

MT Newswires Live06-29

Doximity (DOCS) is facing limited clarity on the execution risks linked to its pivot to artificial intelligence as well as on the near-term trajectory of its revenue and margins, BofA Securities said in a note Monday.

The company is the "industry leader in pharma advertising to physicians" and is also "making the right strategic investments to compete against emerging AI models" like OpenEvidence and OpenAI, according to the note.

However, given that the company's AI peers have "deep pockets" and the top 20 pharma companies already spend significantly with Doximity, there are concerns surrounding Doximity's "ability to grow its current allocations as well as successfully compete for AI dollars," BofA said.

The investment firm also said that since Doximity's earnings before interest, taxes, depreciation, and amortization margin profile is near 50%, investors may be underappreciating the duration and size of the company's future investments.

"While shares are inexpensive, we see downside risk to consensus over the next few years," the firm said.

BofA downgraded Doximity to underperform from buy and cut the company's price target to $20 from $38.

Price: 20.61, Change: -0.27, Percent Change: -1.29

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2647530887?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-29 22:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647530887","market":"nz","top_or_hot":-1,"title":"Doximity Facing Limited Clarity on AI Projects, BofA Says","media":"MT Newswires Live","content":"<html><body><p> Doximity (DOCS) is facing limited clarity on the execution risks linked to its pivot to artificial intelligence as well as on the near-term trajectory of its revenue and margins, BofA Securities said in a note Monday.</p><p>The company is the \"industry leader in pharma advertising to physicians\" and is also \"making the right strategic investments to compete against emerging AI models\" like OpenEvidence and OpenAI, according to the note.</p><p>However, given that the company's AI peers have \"deep pockets\" and the top 20 pharma companies already spend significantly with Doximity, there are concerns surrounding Doximity's \"ability to grow its current allocations as well as successfully compete for AI dollars,\" BofA said.</p><p>The investment firm also said that since Doximity's earnings before interest, taxes, depreciation, and amortization margin profile is near 50%, investors may be underappreciating the duration and size of the company's future investments.</p><p>\"While shares are inexpensive, we see downside risk to consensus over the next few years,\" the firm said.</p><p>BofA downgraded Doximity to underperform from buy and cut the company's price target to $20 from $38.</p><p>Price: 20.61, Change: -0.27, Percent Change: -1.29</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Doximity Facing Limited Clarity on AI Projects, BofA Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDoximity Facing Limited Clarity on AI Projects, BofA Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-29 22:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Doximity (DOCS) is facing limited clarity on the execution risks linked to its pivot to artificial intelligence as well as on the near-term trajectory of its revenue and margins, BofA Securities said in a note Monday.</p><p>The company is the \"industry leader in pharma advertising to physicians\" and is also \"making the right strategic investments to compete against emerging AI models\" like OpenEvidence and OpenAI, according to the note.</p><p>However, given that the company's AI peers have \"deep pockets\" and the top 20 pharma companies already spend significantly with Doximity, there are concerns surrounding Doximity's \"ability to grow its current allocations as well as successfully compete for AI dollars,\" BofA said.</p><p>The investment firm also said that since Doximity's earnings before interest, taxes, depreciation, and amortization margin profile is near 50%, investors may be underappreciating the duration and size of the company's future investments.</p><p>\"While shares are inexpensive, we see downside risk to consensus over the next few years,\" the firm said.</p><p>BofA downgraded Doximity to underperform from buy and cut the company's price target to $20 from $38.</p><p>Price: 20.61, Change: -0.27, Percent Change: -1.29</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4613","symbol_name":"AI应用软件","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2647530887","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647530887","pubTimestamp":1782744339,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Doximity  is facing limited clarity on the execution risks linked to its pivot to artificial intelligence as well as on the near-term trajectory of its revenue and margins, BofA Securities said in a note Monday.The company is the \"industry leader in pharma advertising to physicians\" and is also \"making the right strategic investments to compete against emerging AI models\" like OpenEvidence and OpenAI, according to the note.However, given that the company's AI peers have \"deep pockets\" and the top 20 pharma companies already spend significantly with Doximity, there are concerns surrounding Doximity's \"ability to grow its current allocations as well as successfully compete for AI dollars,\" BofA said.The investment firm also said that since Doximity's earnings before interest, taxes, depreciation, and amortization margin profile is near 50%, investors may be underappreciating the duration and size of the company's future investments.\"While shares are inexpensive, we see downside risk to c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4613":"AI应用软件","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","BK4585":"ETF&股票定投概念","AGIX":"通用人工智能 ETF-AGIX","BK4167":"医疗保健技术","DOCS":"Doximity, Inc.","BK4539":"次新股","ARTY":"ISHARES FUTURE AI & TECH ETF","BK4551":"寇图资本持仓","AIPO":"Defiance AI and Power Infrastructure ETF","BK4588":"碎股"},"translate_title":"美国银行表示，Doximity在人工智能项目方面面临有限的清晰度","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARTY":1.5,"AGIX":1.5,"AIPO":1.5,"CHAT":1.5,"DOCS":1.5},"content_text":"Doximity (DOCS) is facing limited clarity on the execution risks linked to its pivot to artificial intelligence as well as on the near-term trajectory of its revenue and margins, BofA Securities said in a note Monday.The company is the \"industry leader in pharma advertising to physicians\" and is also \"making the right strategic investments to compete against emerging AI models\" like OpenEvidence and OpenAI, according to the note.However, given that the company's AI peers have \"deep pockets\" and the top 20 pharma companies already spend significantly with Doximity, there are concerns surrounding Doximity's \"ability to grow its current allocations as well as successfully compete for AI dollars,\" BofA said.The investment firm also said that since Doximity's earnings before interest, taxes, depreciation, and amortization margin profile is near 50%, investors may be underappreciating the duration and size of the company's future investments.\"While shares are inexpensive, we see downside risk to consensus over the next few years,\" the firm said.BofA downgraded Doximity to underperform from buy and cut the company's price target to $20 from $38.Price: 20.61, Change: -0.27, Percent Change: -1.29","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2647530887","isCrawlerRequest":true}